Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.54 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715147 | 0.93 | SMN1; SMN2 (0.73) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL5247422 | 0.91 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL4712758 | 0.87 | SMN1; SMN2 (0.57) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5248158 | 0.87 | SMN1; SMN2 (0.67) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL5739759 | 0.86 | MEN1 (0.52) | SMN1; SMN2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL4715305 | 0.85 | F2 (0.54) | SMN1; SMN2LMNAKMT2APOLBNPC1 | |
| SCHEMBL5252153 | 0.84 | PKM (0.54) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL5739653 | 0.84 | NPC1 (0.56) | SMN1; SMN2ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL5249987 | 0.82 | RAB9A (0.53) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL5252833 | 0.82 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644371-B1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | AVENTIS PHARMA INC (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1519934-B1 | PYRAZOLOISOQUINOLINE DERIVATIVES FOR INHIBITING NF$G(K)B-INDUCING KINASE (NIK) | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-09-19 | — | — | EP | disclosed |
| US-7132428-B2 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1644371-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005012301-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-13 | — | — | US | disclosed |
| US-6841556-B2 | Pyrazoloisoquinoline derivatives for inhibiting NFκB-inducing kinase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-11 | — | — | US | disclosed |
| US-20040097541-A1 | Pyrazoloisoquinoline derivatives for inhibiting NFkappaB-inducing kinase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-20 | — | — | US | disclosed |
| WO-2004005287-A9 | PYRAZOLOISOQUINOLINE DERIVATIVES FOR INHIBITING NFKAPPAB-INDUCING KINASE (NIK) | AVENTIS PHARMA GMBH (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097541-A1 | Pyrazoloisoquinoline derivatives for inhibiting NFkappaB-inducing kinase | NFKBIA, IKBKB, IKBKG | SMN1; SMN2 3029/4885LMNA 2200/4885ALDH1A1 3472/4885 |
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | PRKDC, MAP3K2, MAP3K20 | SMN1; SMN2 1475/4885LMNA 1662/4885ALDH1A1 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.